Foretinib | CAS# 849217-64-7

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

Other drug agents

Drug intermediates

Bio-reagents and biochemicals

MedKoo product information:

Foretinib

Foretinib is an orally bioavailable small molecule with potential antineoplastic activity. MET/VEGFR2 inhibitor GSK1363089 binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers. VEGFR2 is found on endothelial and hematopoietic cells and mediates the development of the vasculature and hematopoietic cells through VEGF signaling. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Current developer: Telik Inc.

MedKoo Code#: 201372

Name: Foretinib

CAS#: 849217-64-7

Synonym: XL880, SK1363089, GSK089, EXEL-2880; GSK1363089

　

IUPAC/Chemical name:

N-(3-fluoro-4-((6-methoxy-7-(3-morpholinopropoxy)quinolin-4-yl)oxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.

Chemical structure:

Theoretical analysis

MedKoo Code#: 201372
Name: Foretinib
CAS#: 849217-64-7

Chemical Formula: C34H34F2N4O6
Exact Mass: 632.24464
Molecular Weight: 632.65377
Elemental Analysis: C, 64.55; H, 5.42; F, 6.01; N, 8.86; O, 15.17

Availability and price:

Foretinib (99%) is in stock

10 mg / $290.00

50 mg / $850.00

100 mg / $1,550.00

To inquire quotation and lead time or to ask questions, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer big discount for orders of bulk quantities.

Quality control data:

Product will be shipped with supporting analytical data.

Information about this agent

References

1: Eder JP, Shapiro GI, Appleman L, Zhu AX, Miles D, Keer HN, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum SW, Heath EI, Boerner SA, Lorusso P. A Phase I Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Early Antitumor Activity of Foretinib. Clin Cancer Res. 2010 May 14. [Epub ahead of print] PubMed PMID: 20472683.

2: Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol. 2010 Apr 4. [Epub ahead of print] PubMed PMID: 20371362.

3: Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009 Sep 1;69(17):6871-8. Epub 2009 Aug 11. PubMed PMID: 19671800.

Contact MedKoo:

Email: sales@medkoo.com

(Keyword; CAS#; MedKoo code#)